Completed PHASE2 INTERVENTIONAL 4-arm NCT00540670

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Sponsor: Eisai Co., Ltd.

Interventions E5555 100 mg E5555 200 mg E5555 50 mg Placebo

Updated 6 times since 2017 Last updated: May 9, 2013 Started: Oct 31, 2007 Primary completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Eisai Co., Ltd. and has accumulated 6 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Co., Ltd.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asahikawa, Japan , Bunkyo-ku, Japan , Chitose, Japan , Gifu, Japan , Himeji, Japan , Ichinomiya, Japan , Kanazawa, Japan , Kitamoto, Japan , Kumamoto, Japan , Matsusaka, Japan and 15 more locations